跳至主要内容
临床试验/JPRN-jRCT1080223147
JPRN-jRCT1080223147已完成Unknown

Special Drug Use Surveillance of Takecab Tablets for Maintenance Therapy of Reflux Esophagitis: Long-term Use

Takeda Pharmaceutical Company Limited0 个研究点目标入组 1,237 人开始时间: 2016年3月16日最近更新:

试验速览

阶段
Unknown
状态
已完成
入组人数
1,237

研究概览

简要总结

In conclusion, from the results stated above, this surveillance raised no new concerns about the safety or efficacy of long-term use of Takecab Tablets as maintenance therapy for reflux esophagitis. Please refer to conclusions of "Adverse Events" and "Secondary Outcome Measures" sections for the details.

研究设计

研究类型
Observational

入排标准

年龄范围
ot applicable 至 ot applicable(—)
性别
All

入选标准

  • Participants who require maintenance therapy for relapsed/recurrent reflux esophagitis.

排除标准

  • 1. Participants meeting the criteria of grade A to D according to the Los Angeles classification (Hoshihara's modification), by means of endoscopy at the initiation of maintenance therapy with vonoprazan tablets.
  • 2. Participants with a previous history of hypersensitivity to ingredients in vonoprazan tablets.
  • 3. Participants taking atazanavir sulfate or rilpivirine hydrochloride.

研究者

相似试验